A detailed history of Groupama Asset Managment transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Groupama Asset Managment holds 78,045 shares of DNLI stock, worth $1.93 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
78,045
Previous 72,388 7.81%
Holding current value
$1.93 Million
Previous $1.68 Billion 8.59%
% of portfolio
0.05%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$20.96 - $31.05 $118,570 - $175,649
5,657 Added 7.81%
78,045 $1.83 Billion
Q2 2024

Aug 14, 2024

BUY
$14.96 - $23.22 $427,272 - $663,186
28,561 Added 65.17%
72,388 $1.68 Billion
Q1 2024

May 14, 2024

BUY
$15.83 - $23.35 $139,525 - $205,806
8,814 Added 25.17%
43,827 $899 Million
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $567,210 - $811,601
35,013 New
35,013 $752 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.31B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Groupama Asset Managment Portfolio

Follow Groupama Asset Managment and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Groupama Asset Managment, based on Form 13F filings with the SEC.

News

Stay updated on Groupama Asset Managment with notifications on news.